Clinical trials: Dengue Hemorrhagic Fever
DENV-3 Controlled Human Infection Model
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
- Trial name
- NCT06799741
- Testing
- AV-1 100 mg, AV-1 300 mg, AV-1 900 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Dengue
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
- Trial name
- NCT01702272
- Testing
- Procleix Dengue Virus Assay
- Where
- United States
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Dengue
Study of Dengue in Patients With Autoimmune Diseases During the Epidemics of 2020 and 2021 in Reunion Island
It is not known whether there is a different clinical profile of dengue in patients with immune system dysfunction. Preliminary data and previous literature suggest that autoimmune diseases, and in particular their treatment, may…
- Trial name
- MAIDEN (NCT05852977)
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Dengue, Dengue Hemorrhagic Fever
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
The study was designed to evaluate whether the first CYD dengue vaccination can be administered concomitantly with Stamaril® yellow fever vaccine during the same day and visit, but at 2 different sites of administration.
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Yellow Fever
- Trial name
- NCT01436396
- Testing
- Live, attenuated dengue serotype 1, 2, 3, and 4 virus, Yellow fever vaccine, Measles, mumps, and rubella (MMR) vaccine
- Where
- 2 sites in Colombia, Peru
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
Infection with dengue viruses is one of the leading causes of hospitalization and death in children in several tropical Asian counties.
- Trial name
- NCT00919178
- Testing
- DEN4 Vaccine Candidate
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Laboratory Diagnosis and Prognosis of Severe Dengue
A study of dengue in children presenting to outpatient departments of 5 large hospitals in Ho Chi Minh City and Tien Giang province, Viet Nam.
- Trial name
- NCT01421732
- Where
- Vietnam
- Volunteers
- 8,100 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Emerging Infectious Diseases, COVID-19
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health.
- Conditions
- Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox)
- Trial name
- SMART-ID (NCT07678619)
- Testing
- Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Peking University
Dengue Fever
Role of Andi-d in Dengue Fever: a Pilot Study
The purpose of this study is evaluate the role of anti-d in dengue fever.
- Trial name
- NCT01443247
- Testing
- anti-d
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Dengue Fever
Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease
This is a phase 1 study to evaluate the safety of a vaccine (DENV-1 PIV) for the prevention of dengue fever.
- Trial name
- DENV-1 PIV (NCT01502735)
- Testing
- DENV-1 PIV, 2.5 µg, DENV-1 PIV, 5 µg
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue, Dengue Fever
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
The aim of the trial was to assess the efficacy of the CYD dengue vaccine in preventing symptomatic, virologically-confirmed dengue (VCD) cases.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01373281
- Testing
- Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- Where
- 12 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 10,275 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Educational Intervention to Promote Control Behaviors and Prevention of Dengue
This study will assess the effect of an educational nursing intervention in adults to promote dengue control and prevention behaviors, in comparison with the usual strategy of a health service provider institution.
- Trial name
- NCT05321264
- Testing
- Educational nursing intervention
- Where
- Colombia
- Volunteers
- 116 people
- Sponsor
- Universidad de Antioquia
Travel-Related Illness, Malaria
Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
The investigators hypothesize that sex, age, area of exposure and purpose of travel are associated with different travel-related infections. The investigators also hypothesize that certain infections will have long-term sequelae.
- Conditions
- Travel-Related Illness, Malaria, Dengue, Chikungunya
- Trial name
- ITIT (NCT04672577)
- Testing
- Observational study
- Where
- Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Patricia Schlagenhauf
Dengue
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model.
- Trial name
- NCT02372175
- Testing
- Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue Fever
Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)
The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are: Is Resomelagon safe to use in patients with Dengue? Is…
- Trial name
- RESOVIR-2 (NCT06917001)
- Testing
- Resomelagon, Standard Treatment
- Where
- 2 sites in Brazil
- Volunteers
- 120 people
- Sponsor
- Federal University of Minas Gerais
Dengue Fever
A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for Dengue
The main aim of this study is to collect more information on the effectiveness of TDV when used in a pilot public vaccination program for children and adolescents participating in a community-based cohort in Southeast Asian…
- Trial name
- NCT06843226
- Testing
- No Intervention
- Where
- 7 sites in Indonesia, Malaysia and 1 more
- Volunteers
- 70,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1.
- Trial name
- NCT07016321
- Testing
- Emetine Hydrochloride 6mg, Emetine Hydrochloride 12mg
- Where
- 2 sites in United States, Nepal
- Volunteers
- 600 people
- Sponsor
- Johns Hopkins University
Dengue
Impact of Project Wolbachia - Singapore on Dengue Incidence
The study is a cluster-randomised controlled trial set in Singapore, to assess if the deployment of male Wolbachia-infected Aedes aegypti mosquitoes can reduce dengue incidence in intervention clusters.
- Trial name
- NCT05505682
- Testing
- Biological (Male Wolbachia-infected Aedes aegypti)
- Where
- Singapore
- Volunteers
- 724,428 people
- Sponsor
- National Environment Agency, Singapore
Dengue
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Dengue viruses infect millions of people throughout the tropics and subtropics each year. The development of a dengue vaccine is an important health priority.
- Trial name
- NCT02392325
- Testing
- rDEN1Δ30, rDEN2Δ30-7169
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
The purpose of this study is to assess the safety of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) (previously DENVax) in healthy adults when given as either a subcutaneous (SC) or intradermal (ID) injection at two dose…
- Trial name
- NCT01224639
- Testing
- TDV - Low Dose, TDV - High Dose
- Where
- Colombia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Inviragen Inc.
Dengue Fever
Factors Associated With Poor Dengue Outcomes in Malaysia
This study aims to analyse the results of national data collected by the e-Dengue Information System in order to determine the factors associated with disease outcomes in all patients registered from January 2013 to December 2014.
- Trial name
- NCT02510690
- Where
- Malaysia
- Volunteers
- 20,000 people
- Sponsor
- Clinical Research Centre, Malaysia